Evaluation of the plasma concentration of ponatinib in a chronic myeloid leukaemia patient with ponatinib intolerance

被引：3

作者：

Abumiya, Maiko ^{[1
]}

Takahashi, Naoto ^{[2
]}

Yoshioka, Tomoko ^{[2
]}

Kameoka, Yoshihiro ^{[2
,3
]}

Miura, Masatomo ^{[1
]}

机构：

[1] Akita Univ Hosp, Dept Pharm, Akita, Japan

[2] Akita Univ, Grad Sch Med, Dept Hematol Nephrol & Rheumatol, 1-1-1 Hondo, Akita, Akita 0108543, Japan

[3] Akita Univ Hosp, Clin Res Promot & Support Ctr, Akita, Japan

来源：

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 2021年 / 46卷 / 01期

关键词：

bioavailability; chronic myeloid leukaemia; intolerance; plasma concentrations; ponatinib; METABOLISM;

D O I：

10.1111/jcpt.13257

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

What is known and objective Some patients with chronic myeloid leukaemia (CML) cannot continue tyrosine kinase inhibitor (TKI) treatment due to intolerance associated with higher plasma concentration. Case summary A 76-year-old woman with chronic-phase CML who showed resistance/intolerance to pre-TKIs has been treated with ponatinib. A high ponatinib bioavailability was noted; therefore, we administered ponatinib 15 mg/3 d to avoid adverse events due to high exposure. Eventually, the patient achieved a major molecular response. What is new and conclusion Monitoring of the ponatinib plasma concentration led to safe and effective CML management in a patient with higher drug bioavailability.

引用

页码：219 / 222

页数：4

共 10 条

[1]

Abumiya M, 2017, LEUKEMIA RES, V64, P42

[2]

[Anonymous], 2020, NCCN Clinical Practice Guidelines in Oncology: Survivorship

[3] European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 [J].

Baccarani, Michele ;

Deininger, Michael W. ;

Rosti, Gianantonio ;

Hochhaus, Andreas ;

Soverini, Simona ;

Apperley, Jane F. ;

Cervantes, Francisco ;

Clark, Richard E. ;

Cortes, Jorge E. ;

Guilhot, Francois ;

Hjorth-Hansen, Henrik ;

Hughes, Timothy P. ;

Kantarjian, Hagop M. ;

Kim, Dong-Wook ;

Larson, Richard A. ;

Lipton, Jeffrey H. ;

Mahon, Francois-Xavier ;

Martinelli, Giovanni ;

Mayer, Jiri ;

Mueller, Martin C. ;

Niederwieser, Dietger ;

Pane, Fabrizio ;

Radich, Jerald P. ;

Rousselot, Philippe ;

Saglio, Giuseppe ;

Saussele, Susanne ;

Schiffer, Charles ;

Silver, Richard ;

Simonsson, Bengt ;

Steegmann, Juan-Luis ;

Goldman, John M. ;

Hehlmann, Ruediger .

BLOOD, 2013, 122 (06) :872-884

[4] Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients [J].

Dorer, David J. ;

Knickerbocker, Ronald K. ;

Baccarani, Michele ;

Cortes, Jorge E. ;

Hochhaus, Andreas ;

Talpaz, Moshe ;

Haluska, Frank G. .

LEUKEMIA RESEARCH, 2016, 48 :84-91

[5] The Influence of Chronic Renal Failure on Drug Metabolism and Transport [J].

Dreisbach, A. W. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (05) :553-556

[6] Tacrolimus pharmacogenetics: Polymorphisms associated with expression of cytochrome P4503A5 and P-glycoprotein correlate with dose requirement [J].

Macphee, IAM ;

Fredericks, S ;

Tai, T ;

Syrris, P ;

Carter, ND ;

Johnston, A ;

Goldberg, L ;

Holt, DW .

TRANSPLANTATION, 2002, 74 (11) :1486-1489

[7] AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance [J].

O'Hare, Thomas ;

Shakespeare, William C. ;

Zhu, Xiaotian ;

Eide, Christopher A. ;

Rivera, Victor M. ;

Wang, Frank ;

Adrian, Lauren T. ;

Zhou, Tianjun ;

Huang, Wei-Sheng ;

Xu, Qihong ;

Metcalf, Chester A., III ;

Tyner, Jeffrey W. ;

Loriaux, Marc M. ;

Corbin, Amie S. ;

Wardwell, Scott ;

Ning, Yaoyu ;

Keats, Jeffrey A. ;

Wang, Yihan ;

Sundaramoorthi, Raji ;

Thomas, Mathew ;

Zhou, Dong ;

Snodgrass, Joseph ;

Commodore, Lois ;

Sawyer, Tomi K. ;

Dalgarno, David C. ;

Deininger, Michael W. N. ;

Druker, Brian J. ;

Clackson, Tim .

CANCER CELL, 2009, 16 (05) :401-412

[8] Influence of CYP3A5 Polymorphism on the Pharmacokinetics of Psychiatric Drugs [J].

Ragia, Georgia ;

Dahl, Marja-Liisa ;

Manolopoulos, Vangelis G. .

CURRENT DRUG METABOLISM, 2016, 17 (03) :227-236

[9] Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study [J].

Tojo, Arinobu ;

Kyo, Taiichi ;

Yamamoto, Kazuhito ;

Nakamae, Hirohisa ;

Takahashi, Naoto ;

Kobayashi, Yukio ;

Tauchi, Tetsuzo ;

Okamoto, Shinichiro ;

Miyamura, Koichi ;

Hatake, Kiyohiko ;

Iwasaki, Hiromi ;

Matsumura, Itaru ;

Usui, Noriko ;

Naoe, Tomoki ;

Tugnait, Meera ;

Narasimhan, Narayana I. ;

Lustgarten, Stephanie ;

Farin, Heinrich ;

Haluska, Frank ;

Ohyashiki, Kazuma .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (03) :385-397

[10] Absorption, metabolism, and excretion of [14C]ponatinib after a single oral dose in humans [J].

Ye, Yihua E. ;

Woodward, Caroline N. ;

Narasimhan, Narayana I. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) :507-518

← 1 →